Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Markert

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|February 19, 2000
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumorsJ N Parker, G Y Gillespie, C E Love, et al.
Cancer Gene Therapy|September 23, 2006
Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumorsM B Guffey, J N Parker, W S Luckett, et al.
Cancer Research|April 15, 1997
Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumorsS Andreansky, L Soroceanu, E R Flotte, et al.
Gene Therapy|April 13, 2007
Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic virusesA C Shah, J N Parker, G Y Gillespie, et al.
The Journal of Biological Chemistry|August 22, 2001
pH alterations "reset" Ca2+ sensitivity of brain Na+ channel 2, a degenerin/epithelial Na+ ion channel, in planar lipid bilayersB K Berdiev, T B Mapstone, J M Markert, et al.
Gene Therapy|April 16, 1998
Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukinsS Andreansky, B He, J van Cott, et al.
Gene Therapy|May 6, 2011
Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1S J Advani, J M Markert, R F Sood, et al.
Cancer Research|May 8, 1999
Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumorsS J Advani, S M Chung, S Y Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 1999
Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virusJ D Bradley, Y Kataoka, S Advani, et al.
Gene Therapy|August 15, 2014
Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell linesJ D Jackson, A M McMorris, J C Roth, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Proceedings of the National Academy of Sciences of the United States of America|February 19, 2000
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumorsJ N Parker, G Y Gillespie, C E Love, et al.
Cancer Gene Therapy|September 23, 2006
Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumorsM B Guffey, J N Parker, W S Luckett, et al.
Cancer Research|April 15, 1997
Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumorsS Andreansky, L Soroceanu, E R Flotte, et al.
Gene Therapy|April 13, 2007
Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic virusesA C Shah, J N Parker, G Y Gillespie, et al.
The Journal of Biological Chemistry|August 22, 2001
pH alterations "reset" Ca2+ sensitivity of brain Na+ channel 2, a degenerin/epithelial Na+ ion channel, in planar lipid bilayersB K Berdiev, T B Mapstone, J M Markert, et al.
Gene Therapy|April 16, 1998
Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukinsS Andreansky, B He, J van Cott, et al.
Gene Therapy|May 6, 2011
Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1S J Advani, J M Markert, R F Sood, et al.
Cancer Research|May 8, 1999
Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumorsS J Advani, S M Chung, S Y Yan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 2, 1999
Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virusJ D Bradley, Y Kataoka, S Advani, et al.
Gene Therapy|August 15, 2014
Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell linesJ D Jackson, A M McMorris, J C Roth, et al.
Pageof 3